Research advances in myosteatosis in chronic liver diseases

Jintao SUN; Fengxia LI

doi:10.3969/j.issn.1001-5256.2023.02.031

Volume 39 Issue 2

Feb. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(2): 444-449

PDF( 2465 KB)

Research advances in myosteatosis in chronic liver diseases

DOI: 10.3969/j.issn.1001-5256.2023.02.031

Jintao SUN,
Fengxia LI^{,
,}

Department of Gastroenterology, The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan 030012, China

Research funding:

Shanxi Province Key Medical Science and Technology Project (2020XM23)

More Information

Corresponding author: LI Fengxia, doctorlfx@163.com (ORCID: 0000-0002-6712-0491)
Received Date: 2022-07-01
Accepted Date: 2022-08-12
Published Date: 2023-02-20

Abstract

Abstract

Myosteatosis is the main manifestation of malnutrition and is a common complication of chronic liver diseases, with a negative impact on the progression and prognosis of liver diseases. There is no gold standard for the diagnosis of myosteatosis, and CT is a commonly used diagnostic method. Myosteatosis in chronic liver diseases has diverse mechanisms, and hyperammonemia, increased cathepsin D level in circulation, insulin resistance, mitochondrial dysfunction, and chronic systemic microinflammation play an important role in myosteatosis. Early intervention of these factors can improve prognosis. With reference to related studies in China and globally, this article reviews the features, diagnostic methods, pathogenesis, treatment, and intervention of myosteatosis.
- Liver Diseases,
- Malnutrition,
- Myosteatosis,
- Pathological Conditions, Signs and Symptoms

FullText(HTML)

References(29)

References

[1]	EBADI M, TSIEN C, BHANJI RA, et al. Myosteatosis in cirrhosis: a review of diagnosis, pathophysiological mechanisms and potential interventions[J]. Cells, 2022, 11(7). DOI: 10.3390/cells11071216.
[2]	BHANJI RA, MOCTEZUMA-VELAZQUEZ C, DUARTE-ROJO A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis[J]. Hepatol Int, 2018, 12(4): 377-386. DOI: 10.1007/s12072-018-9875-9.
[3]	FENG H, WANG X, MAO L, et al. Relationship between sarcopenia/myosteatosis and frailty in hospitalized patients with cirrhosis: a sex-stratified analysis[J]. Ther Adv Chronic Dis, 2021, 12: 20406223211026996. DOI: 10.1177/20406223211026996.
[4]	MONTANO-LOZA AJ, ANGULO P, MEZA-JUNCO J, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis[J]. J Cachexia Sarcopenia Muscle, 2016, 7(2): 126-135. DOI: 10.1002/jcsm.12039.
[5]	LIU YY, CHEN DF, YAN QX. Current status of the pathogenesis, diagnosis, and treatment of sarcopenia in patients with liver cirrhosis[J]. J Clin Hepatol, 2022, 38(1): 191-195. DOI: 10.3696/j.issn.1001-5256.2022.01.033. 刘钰懿, 陈东风, 颜綦先. 肝硬化肌少症的发病机制与诊疗现状[J]. 临床肝胆病杂志, 2022, 38(1): 191-195. DOI: 10.3696/j.issn.1001-5256.2022.01.033.
[6]	GUMUCIO JP, QASAWA AH, FERRARA PJ, et al. Reduced mitochondrial lipid oxidation leads to fat accumulation in myosteatosis[J]. FASEB J, 2019, 33(7): 7863-7881. DOI: 10.1096/fj.201802457RR.
[7]	KHURANA P, YADATI T, GOYAL S, et al. Inhibiting extracellular cathepsin d reduces hepatic steatosis in sprague-dawley rats[J]. Biomolecules, 2019, 9(5): 171. DOI: 10.3390/biom9050171.
[8]	KANG JK, KIM OH, HUR J, et al. Increased intracellular Ca2+ concentrations prevent membrane localization of PH domains through the formation of Ca2+-phosphoinositides[J]. Proc Natl Acad Sci U S A, 2017, 114(45): 11926-11931. DOI: 10.1073/pnas.1706489114.
[9]	DING L, DE MUNCK T, OLIGSCHLAEGER Y, et al. Myosteatosis in NAFLD patients correlates with plasma Cathepsin D[J]. Biomol Concepts, 2021, 12(1): 27-35. DOI: 10.1515/bmc-2021-0004.
[10]	DING L, HOUBEN T, OLIGSCHLAEGER Y, et al. Plasma cathepsin d activity rather than levels correlates with metabolic parameters of type 2 diabetes in male individuals[J]. Front Endocrinol (Lausanne), 2020, 11: 575070. DOI: 10.3389/fendo.2020.575070.
[11]	DONGIOVANNI P, STENDER S, PIETRELLI A, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver[J]. J Intern Med, 2018, 283(4): 356-370. DOI: 10.1111/joim.12719.
[12]	PETERSEN MC, SHULMAN GI. Mechanisms of Insulin action and insulin resistance[J]. Physiol Rev, 2018, 98(4): 2133-2223. DOI: 10.1152/physrev.00063.2017.
[13]	JANA BA, CHINTAMANENI PK, KRISHNAMURTHY PT, et al. Cytosolic lipid excess-induced mitochondrial dysfunction is the cause or effect of high fat diet-induced skeletal muscle insulin resistance: a molecular insight[J]. Mol Biol Rep, 2019, 46(1): 957-963. DOI: 10.1007/s11033-018-4551-7.
[14]	MORALES PE, BUCAREY JL, ESPINOSA A. Muscle lipid metabolism: role of lipid droplets and perilipins[J]. J Diabetes Res, 2017, 2017: 1789395. DOI: 10.1155/2017/1789395.
[15]	ZHANG LR, WANG SQ, WANG HY, et al. Effect of mitochondrial dysfunction introduced by chronic liver injury in rats[J]. J China Med Univ, 2020, 49(8): 747-751. DOI: 10.12007/j.issn.0258-4646.2020.08.015. 张靓睿, 王诗琪, 王红昀, 等. 大鼠慢性肝损伤的线粒体功能障碍及其影响[J]. 中国医科大学学报, 2020, 49(8): 747-751. DOI: 10.12007/j.issn.0258-4646.2020.08.015.
[16]	LI CW, YU K, SHYH-CHANG N, et al. Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review[J]. J Cachexia Sarcopenia Muscle, 2022, 13(2): 781-794. DOI: 10.1002/jcsm.12901.
[17]	MOROZZI G, BECCAFICO S, BIANCHI R, et al. Oxidative stress-induced S100B accumulation converts myoblasts into brown adipocytes via an NF-κB/YY1/miR-133 axis and NF-κB/YY1/BMP-7 axis[J]. Cell Death Differ, 2017, 24(12): 2077-2088. DOI: 10.1038/cdd.2017.132.
[18]	HAN J, MENG Q, SHEN L, et al. Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning[J]. Lipids Health Dis, 2018, 17(1): 14. DOI: 10.1186/s12944-018-0657-0.
[19]	MASTROCOLA R, COLLINO M, NIGRO D, et al. Accumulation of advanced glycation end-products and activation of the SCAP/SREBP Lipogenetic pathway occur in diet-induced obese mouse skeletal muscle[J]. PLoS One, 2015, 10(3): e0119587. DOI: 10.1371/journal.pone.0119587.
[20]	NACHIT M, DE RUDDER M, THISSEN JP, et al. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models[J]. J Cachexia Sarcopenia Muscle, 2021, 12(1): 144-158. DOI: 10.1002/jcsm.12646.
[21]	BHANJI RA, MOCTEZUMA-VELAZQUEZ C, DUARTE-ROJO A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis[J]. Hepatol Int, 2018, 12(4): 377-386. DOI: 10.1007/s12072-018-9875-9.
[22]	LATTANZI B, NARDELLI S, PIGLIACELLI A, et al. The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease[J]. Dig Liver Dis, 2019, 51(11): 1508-1512. DOI: 10.1016/j.dld.2019.09.004.
[23]	TSIEN C, DAVULURI G, SINGH D, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis[J]. Hepatology, 2015, 61(6): 2018-2029. DOI: 10.1002/hep.27717.
[24]	KUMAR A, DAVULURI G, SILVA R, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis[J]. Hepatology, 2017, 65(6): 2045-2058. DOI: 10.1002/hep.29107.
[25]	KAPOOR B, KAPOOR D, GAUTAM S, et al. Dietary Polyunsaturated Fatty Acids (PUFAs): Uses and potential health benefits[J]. Curr Nutr Rep, 2021, 10(3): 232-242. DOI: 10.1007/s13668-021-00363-3.
[26]	ALMASUD AA, GILES KH, MIKLAVCIC JJ, et al. Fish oil mitigates myosteatosis and improves chemotherapy efficacy in a preclinical model of colon cancer[J]. PLoS One, 2017, 12(8): e0183576. DOI: 10.1371/journal.pone.0183576.
[27]	YOUNOSSI ZM, COREY KE, LIM JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review[J]. Gastroenterology, 2021, 160(3): 912-918. DOI: 10.1053/j.gastro.2020.11.051.
[28]	GATINEAU E, POLAKOF S, DARDEVET D, et al. Similarities and interactions between the ageing process and high chronic intake of added sugars[J]. Nutr Res Rev, 2017, 30(2): 191-207. DOI: 10.1017/S0954422417000051.
[29]	van DRONKELAAR C, van VELZEN A, ABDELRAZEK M, et al. Minerals and sarcopenia; the role of calcium, iron, magnesium, phosphorus, potassium, selenium, sodium, and zinc on muscle mass, muscle strength, and physical performance in older adults: A systematic review[J]. J Am Med Dir Assoc, 2018, 19(1): 6-11. e3. DOI: 10.1016/j.jamda.2017.05.026.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (640) PDF downloads(64)

Research advances in myosteatosis in chronic liver diseases

DOI: 10.3969/j.issn.1001-5256.2023.02.031

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in myosteatosis in chronic liver diseases

DOI: 10.3969/j.issn.1001-5256.2023.02.031

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content